- Home
- BTX vs TBPH Comparison
BTX vs TBPH Comparison
Compare BTX & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTX | TBPH |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.3M | 824.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BTX | TBPH |
|---|---|---|
| Price | $8.91 | $16.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | ★ 704.0K | 282.6K |
| Earning Date | 11-01-2025 | 05-04-2026 |
| Dividend Yield | ★ 9.94% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.13 | $9.10 |
| 52 Week High | $8.94 | $21.03 |
Technical Indicators
Market Signals| Indicator | BTX | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 70.34 | 46.74 |
| Support Level | $6.23 | $16.14 |
| Resistance Level | $8.94 | $17.21 |
| Average True Range (ATR) | 0.23 | 0.38 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 90.48 | 29.31 |
Price Performance
Historical ComparisonAbout BTX BlackRock Technology and Private Equity Term Trust
BlackRock Technology and Private Equity Term Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.